General Information of Drug (ID: DMQIWZL)

Drug Name
Candoxatrilat Drug Info
Synonyms
Candoxatrilat < Rec INN; UK-69578; UK-73967; Cis-4-[[[1-[2-Carboxy-3-(2-methoxyethoxy)propyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid; (+)-cis-4-[1-[(S)-2-Carboxy-3-(2-methoxyethoxy)propyl]cyclopentylcarbonylamino]cyclohexanecarboxylic acid; 3-[1-(4-cis-Carboxycyclohexylcarbamoyl)cyclopentyl]-2(R,S)-(2-methoxyethoxymethyl)propanoic acid
Indication
Disease Entry ICD 11 Status REF
Heart failure BD10-BD13 Discontinued in Phase 1 [1]
Cross-matching ID
PubChem CID
443380
ChEBI ID
CHEBI:3354
CAS Number
CAS 123122-54-3
TTD Drug ID
DMQIWZL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Neutral endopeptidase (MME)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LCZ696 DMLFX7K Heart failure BD10-BD13 Approved [4]
Candoxatril DMHJCGV Hypertension BA00-BA04 Phase 3 [5]
Gallopamil DMXBR27 Asthma CA23 Phase 2 [6]
SLV 306 DMCDON3 Acute decompensated heart failure BD1Z Phase 2 [7]
SLV-334 DMXCJKY Brain injury NA07.Z Phase 2 [8]
VX-15 DMLWM4G Huntington disease 8A01.10 Phase 2 [9]
Sampatrilat DMXTOVE Hypotension BA20-BA21 Phase 2 [10]
SLV-338 DM7WKTM Cardiovascular disease BA00-BE2Z Phase 1 [11]
GW-796406 DMQ46DN Hypotension BA20-BA21 Phase 1 [6]
Debio 0827 DMQIEFB Chronic pain MG30 Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Neprilysin (MME)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [13]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [14]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [15]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [16]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [17]
Folic Acid DMEMBJC Colorectal carcinoma Approved [18]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [19]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [20]
Arsenic DMTL2Y1 N. A. N. A. Approved [21]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [22]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [23]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [24]
Arsenic DMTL2Y1 N. A. N. A. Approved [25]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [26]
Omapatrilat DMAGUY0 Hypertension BA00-BA04 Terminated [3]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [27]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neutral endopeptidase (MME) TT5TKPM NEP_HUMAN Inhibitor [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Membrane metallo-endopeptidase-like 1 (MMEL1) OTOGJEXZ MMEL1_HUMAN Gene/Protein Processing [3]
Neprilysin (MME) OT5Q39P8 NEP_HUMAN Gene/Protein Processing [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6491).
2 Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens. 1992 Mar;10(3):271-7.
3 Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol. 2008 Mar;153(5):947-55. doi: 10.1038/sj.bjp.0707641. Epub 2007 Dec 17.
4 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
5 Neutral endopeptidase inhibitor suppresses the early phase of atrial electrical remodeling in a canine rapid atrial pacing model. Indian Pacing Electrophysiol J. 2008 Apr 1;8(2):102-13.
6 Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
7 The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8.
8 Clinical trials in traumatic brain injury: past experience and current developments.Neurotherapeutics.2010 Jan;7(1):115-26.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999 Jun;12(6):563-71.
11 Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab. 2011;57(7-8):507-15.
12 Clinical pipeline report, company report or official report of Debiopharm (2011).
13 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
14 Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin. J Soc Gynecol Investig. 2005 Oct;12(7):e55-67.
15 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
16 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
17 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
18 Folate deficiency in normal human fibroblasts leads to altered expression of genes primarily linked to cell signaling, the cytoskeleton and extracellular matrix. J Nutr Biochem. 2007 Aug;18(8):541-52. doi: 10.1016/j.jnutbio.2006.11.002. Epub 2007 Feb 22.
19 Niclosamide, an oral antihelmintic drug, exhibits antimetastatic activity in hepatocellular carcinoma cells through downregulating twist-mediated CD10 expression. Environ Toxicol. 2018 Jun;33(6):659-669.
20 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
21 Fetal-sex dependent genomic responses in the circulating lymphocytes of arsenic-exposed pregnant women in New Hampshire. Reprod Toxicol. 2017 Oct;73:184-195. doi: 10.1016/j.reprotox.2017.07.023. Epub 2017 Aug 6.
22 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
23 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
24 The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
25 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
26 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
27 Comparison of transcriptome expression alterations by chronic exposure to low-dose bisphenol A in different subtypes of breast cancer cells. Toxicol Appl Pharmacol. 2019 Dec 15;385:114814. doi: 10.1016/j.taap.2019.114814. Epub 2019 Nov 9.